Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pascal Woaye-Hune

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Health and Quality of Life Outcomes|May 29, 2020
Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported OutcomesPascal Woaye-Hune, Jean-Benoit Hardouin, Paul-Antoine Lehur, et al.
British Journal of Haematology|September 4, 2024
Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpuraJulia Weisinger, Raïda Bouzid, Dana Ranta, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 22, 2025
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter StudyTali Eviatar, Dafne Capelusnik, Corrado Campochiaro, et al.
Rheumatology (Oxford, England)|August 7, 2021
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patientsArsène Mekinian, Lucie Biard, Lorenzo Dagna, et al.
RMD Open|June 15, 2023
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective studyArsène Mekinian, Lucie Biard, Dagna Lorenzo, et al.
Rheumatology (Oxford, England)|August 14, 2025
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective studyArsène Mekinian, Sarah Meneses, Lucie Biard, et al.
Annals of the Rheumatic Diseases|May 22, 2024
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEXJerome Hadjadj, Yann Nguyen, Dalila Mouloudj, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Health and Quality of Life Outcomes|May 29, 2020
Practical issues encountered while determining Minimal Clinically Important Difference in Patient-Reported OutcomesPascal Woaye-Hune, Jean-Benoit Hardouin, Paul-Antoine Lehur, et al.
British Journal of Haematology|September 4, 2024
Efficacy and safety of daratumumab in multiresistant immune-mediated thrombotic thrombocytopenic purpuraJulia Weisinger, Raïda Bouzid, Dana Ranta, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|September 22, 2025
Comparative Efficacy and Safety of Anakinra and Canakinumab in Patients With VEXAS Syndrome: An International Multicenter StudyTali Eviatar, Dafne Capelusnik, Corrado Campochiaro, et al.
Rheumatology (Oxford, England)|August 7, 2021
Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patientsArsène Mekinian, Lucie Biard, Lorenzo Dagna, et al.
RMD Open|June 15, 2023
Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective studyArsène Mekinian, Lucie Biard, Dagna Lorenzo, et al.
Rheumatology (Oxford, England)|August 14, 2025
Effectiveness of intravenous infliximab versus subcutaneous adalimumab in Takayasu arteritis: multicenter retrospective studyArsène Mekinian, Sarah Meneses, Lucie Biard, et al.
Annals of the Rheumatic Diseases|May 22, 2024
Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEXJerome Hadjadj, Yann Nguyen, Dalila Mouloudj, et al.
Pageof 1